Insulet sees revenues increase across the board

 - 
Friday, November 3, 2017

BILLERICA, Mass. – Insulet Corp. reported revenues of $121.8 million for the third quarter of 2017, representing year-over-year growth of 28%. Net loss was 2.2 million. For the Omnipod, revenues in the U.S. were $70.1 million for the quarter, a 17% increase, and, internationally, $32.5 million, a 70% increase. Revenue from drug delivery was $19.2 million, a 19% increase. “We achieved strong third quarter results across all of our businesses, particularly in our international business,” said Patrick Sullivan, chairman and CEO. “In addition to our 28% revenue growth, we achieved a 180-basis point improvement in gross margin. We are well on our way to our fiscal 2021 targets of $1 billion in revenue and approaching 70% gross margin.”